Adalta Ltd. · ASX:1AD
Adalta — Advanced Therapies Week 2024
20 slides from Adalta's conference presentation, Jan 22, 2024
Slide 1: JPMorgan Week and Advanced Therapies Week partnering progress; AD-214 Phase I extension update
ASX Announcement | 22 January 2024 AdAlta Limited (ASX:1AD) JPMorgan Week and Advanced Therapies Week partnering progress and presentation; AD-214 Phase I extension study update AdAlta has advanced its AD-214 and i-CAR cell therapy partnering programs during events associated with the JPMorgan Healt
Slide 2: AD-214 partnering leads and Phase I extension study on track
3. Secure access to clinic ready technology that is complementary to the i-body® platform AdAlta CEO and Managing Director, Tim Oldham said: "Our investors and shareholders are extremely interested in our partnering initiatives. While we cannot forecast the success or ultimate value of these, we con
Slide 3: About AdAlta Limited
Tim Oldham The Capital Network CEO & Managing Director Julia Maguire P: +61 3 9479 5159 P: +61 2 8999 3699 E: t.oldham@adalta.com.au E: julia@thecapitalnetwork.com.au About AdAlta Limited AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company i
Slide 4: i-body enabled next generation advanced therapies
i-body® enabled next generation advanced therapies AdAlta Limited (ASX:1AD) Advanced Therapies Workshop Miami 19 January 2024
Slide 5: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 6: AdAlta (ASX:1AD): Progressing multiple transaction opportunities
AdAlta (ASX:1AD): Progressing multiple transaction opportunities Purpose: i-body® targeting for next generation therapeutics Going where antibodies can't to produce high-value, next generation protein and cell therapies for debilitating diseases Discovery business Product development business i-body
Slide 7: AdAlta's portfolio: High value therapeutics addressing challenging diseases
AdAlta’s portfolio: High value therapeutics addressing challenging diseases in fibrosis and immuno-oncology and a platform grow further Fibrosis: degenerative, progressive, fatal AdAlta’s AD-214 could meet a desperate need for new approaches for debilitating diseases of the lung (US$4.3b), kidney (U
Slide 8: i-bodies for advanced therapies
i-bodies for advanced therapies
Slide 9: Invention of i-body technology: first fully human domain antibody system
Invention of i-body® technology: first fully human domain antibody system hNCAM domain 1 scaffold + randomized synthetic shark VNAR-like binding loops • 10% the size of Mab; 50% the size of scFv; CDR3 up to 24 AA • Capable of engaging unique receptor epitopes and inducing unique pharmacology CDR3 CD
Slide 10: An immensely powerful drug discovery platform applicable to multiple therapeutic formats
An immensely powerful drug discovery platform applicable to multiple therapeutic formats Current examples Direct therapeutics For challenging targets, such as GCPRs Future examples AD-214 Manufacturing and delivery • Delivery and expression ex vivo and in Targeting agents Bi-specifics and vivo using
Slide 11: i-bodies enable optimized, multifunctional advanced therapy products
i-bodies enable optimized, multifunctional advanced therapy products when combined with partner platforms TINY i-body® needs LESS room in inserted i-CAR-T example gene, enabling MORE engineered function i-body targeting domain Results in superior, multifunctional Tumor cell advanced therapy products
Slide 12: Case study #1: i-CAR-cell therapies
Co-developed advanced therapy programs: Case study #1: i-CAR-cell therapies
Slide 13: Co-developed multi-specific i-CAR-T products with Carina Biotech
The solution: Co-developed multi-specific i-CAR-T products in development with Carina Biotech (repeatable partnering model) Collaboration overview • AdAlta discovers and supplies i-bodies against solid tumor i-body® platform cell therapy platform associated antigens (targets) • Carina engineer into
Slide 14: i-body enabled CAR-T cells demonstrate in vitro cell killing
i-body enabled CAR-T (i-CAR-T) cells demonstrate in vitro cell killing1 UT CNA4002 CNA4003 CNA4004 LOVO LIM-1215 U87 100 100 100 80 80 80 % Lysis % Lysis 60 % Lysis 60 60 40 40 40 20 20 20 0 0 0 10:1 3:1 1:1 10:1 3:1 1:1 10:1 3:1 1:1 E:T E:T E:T § Cell lines: colorectal cancer (LOVO and LIM1215); gl
Slide 15: Case study #2: i-AAV in vivo production
Co-developed advanced therapy programs: Case study #2: i-AAV in vivo production
Slide 16: AdAlta VNARs delivered to brains of mice with functional effect using AAV-5
AdAlta VNARs delivered to brains of mice with functional effect using AAV-5 (DegenRx owned product) AdAlta discovered VNAR- VNAR-DX001 detected in CA1 region DX001 is highly specific to following direct hippocampal or ICV ab-oligomers injection of AAV-5 vector Improved cognition in rat AZD model (wa
Slide 17: Partnering with AdAlta for Advanced Therapies
Partnering with AdAlta for Advanced Therapies
Slide 18: Partnering with AdAlta brings Australian ecosystem advantages into play
Partnering with AdAlta brings Australian ecosystem advantages into play World class advanced therapies clinical trial and translational research Experienced manufacturing and Geographic, time zone and supply chain economic connectivity with China and Rest of Asia Australia's Advanced Therapies ecosy
Slide 19: Advanced therapies are key for AdAlta's growth strategy
Advanced therapies are key for AdAlta’s growth strategy AdAlta’s three core strategies Near term partnering opportunities v Out-licensing; or 1. Realise the value of lead asset AD-214 v Co-development/asset financing Advanced therapies partnering opportunities v Co-development collaborations in 2. P
Slide 20: A modern targeting system for next generation drugs
A modern targeting system for next generation drugs AdAlta Ltd (ASX:1AD) Presentation to Advanced Therapies Workshop January 2024 For more information please contact: Tim Oldham CEO & Managing Director +61 403 446 665 t.oldham@adalta.com.au Investor Relations The Capital Network Julia Maguire +61 2